| Name
|
Endothelin 1, Human, Porcine
|
| Other Name
|
ET-1
|
| Sequence (Single letter abbreviations)
|
CSCSSLMDKECVYFCHLDIIW
|
| Sequence（Three letter abbreviations）
|
{CYS}{SER}{CYS}{SER}{SER}{LEU}{MET}{ASP}{LYS}{GLU}{CYS}{VAL}{TYR}{PHE}{CYS}{HIS}{LEU}{ASP}{ILE}{ILE}{TRP}
|
| Chemical bridge
|
Disulfide bridges: 1-15 and 3-11
|
| Basic description
|
This peptide is a potent vasoconstrictor, derived from endothelial cells. Potent agonist for ETA and ETB endothelin receptors. Induces the production of hypoxia-inducible factor 1α, and, thus, the production of VEGF.
|
| Solubility
|
The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weight out a smaller portion of the contents.
|
| The molecular weight
|
2491.900
|
| Chemical formula
|
C109H159N25O32S5
|
| The purity
|
> 95%
|
| Storage conditions
|
Store the peptide at -20°C. Keep container tightly closed. Store in a cool dry place.
|
| Annotation
|
Potent vasoconstrictor peptide
|
| Documents
|
|
| Figures
|
|
| Reference
|
Ohkita M, et al. Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells. Exp. Biol. Med.(Maywood). Jun 2006; 231(6): 772-776.
Jackson CD, et al. Expression and localization of human endothelin-converting enzyme-1 isoforms in symptomatic atherosclerotic disease and saphenous vein. Exp. Biol. Med.(Maywood). Jun 2006; 231(6): 794-801.
|
Endothelin 1, Human, Porcine
